Loading stock data…
Oncolytics Biotech Inc. (ONCY)
$0.96+0.01 (+1.45%)
Market ClosedLast close Jun 29
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Oncolytics Biotech Inc. in the Healthcare sector is trading at $0.96 with a market capitalization of $98M. Wall Street consensus targets $4.92 (6 analysts), implying a +411.6% move over the next 12 months. The stock is currently 36% below its 52-week high of $1.51, remaining 5.7% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +411.6% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$9.28M↑ | -$9.65M↑ | -$9.94M↓ | -$4.17M↑ | -$5.02M |
| Net Income | -$9.24M↓ | -$9.18M↑ | -$10.35M↓ | -$4.51M↑ | -$4.71M |
Peer Comparison
JNJUNHPFE
Fundamentals
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treat...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$97.87M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.08
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
648.60%
Volume
Today's trading volume
925,054
Recent News
Sector Update: Healthcare Stocks Advance in Afternoon Trading
Healthcare stocks edged higher Tuesday afternoon, with the NYSE Healthcare Index and the State Stree
ONCY Stock Surged Today – Here’s What Securing A Key Immunotherapy Patent Means For Oncolytics
The U.S. Patent and Trademark Office granted a new patent covering key aspects of its proprietary manufacturing process for its investigational cancer immunotherapy Pelareorep.
Oncolytics Biotech (ONCY) Valuation Check As New Pelareorep RAS Combo Data Draws Investor Attention
Oncolytics Biotech (ONCY) is back on investors’ radars after early preclinical results showed its immunotherapy pelareorep combined with RAS inhibitors produced stronger anti tumor activity than either treatment alone in a solid tumor model. See our latest analysis for Oncolytics Biotech. Even with the recent preclinical update and fresh leadership appointments at the board and COO level, the stock is still trading at US$0.88, with a 1 year total shareholder return of about 1.6x but a 5 year...
ONCY Stock Heads For Sixth Straight Session Of Gains – Lead Therapy Shines in Early Combination Treatment Study
Oncolytics Biotech said preclinical data showed its experimental immunotherapy produced stronger anti-tumor effects in combination therapy, supporting future studies in pancreatic and colorectal cancers.
Oncolytics Biotech Reports Data in Colorectal Cancer Study
By Karen Roman Oncolytics Biotech Inc. (Nasdaq: ONCY) said it has new data showing the use of pelareorep in metastatic colorectal cancer has a 19.5-month median duration of response compared to […]